

Available for Acquisition #201407

Medical & Surgical Equipment Manufacturer

ACT Capital is pleased to offer for acquisition a highly profitable, rocket growth, medical technology company. The Company's core business is advancing the art of aesthetic and regenerative injectables. It designs, patents, and manufactures proprietary medical products for the harvesting, processing, and deployment of FDA 361 compliant autologous soft tissue. Over 300 doctors are using the products in the fields of aesthetic and cosmetic surgery applications, regenerative medicine, pain management, and anti-aging procedures. The Company experienced tremendous acceptance of the products in CA and has now expanded nationally and internationally.

Investment Highlights

- **Proven Product.** The Company produces some of the most innovative technologies that can transfer the patient's own adipose tissue under local anesthesia, with little to no recovery time. It provides the full stack of medical products needed to perform varying types of fat transfer and plastic surgery procedures.
- **Intellectual Property.** The Company is an intellectual property think tank, development company, and distributor specializing in the fields of regenerative aesthetics and medicine. From concept to validation, then manufacturing, the Company is meticulous in how and why it develops the products it does. Its' products are patented and have several patents pending.
- **Clinical Support.** The Company has an expert team of physician advisors and consultants. They provide advice and support to physicians long after the initial sale of the products to ensure favorable outcomes.



Leader in liposuction, adipose tissue collection, fat grafting, and autologous cell isolation and transfer.



Robust research and development team committed to producing the latest and most effective medical equipment.



Strong reputation and relationships with leading doctors and surgeons in the California market.

Innovative New Products

- **2017:** 1st Fully Reusable and Disposable Plastic Systems
- **2018:** 1st Fat Grafting Kit to Transfer Patients Own Adipose Tissue Under Local Aesthetic
- **2020:** Patent Awarded for Super G Micro Cannula – Online Store Launched
- **2021:** National Rollout of Custom Designed Product to Multi-State Body Contouring Co. – Launched Service/Mtce Dept. & Initial Clients

500% Growth in EBITDA from 2019 to 2020.

300% Expected EBITDA Growth in 2021 based on YTD numbers.

100% Expected Revenue Growth in 2021 based on YTD numbers.

Accelerating Revenue & Profit Growth

In 2020, the Company saw record revenue, with growth of over 30%, and profits, which were up 500%. Factors included a new laser sculpting product line, new patented micro cannula products, a new Chief Science Officer, expansion of the sales force, and a multi-year engineering design and product provisioning contract. As 2021 overachieves with more than 100% revenue growth and EBITDA tripling, it added a regulatory division, opened additional distribution channels in Canada, Japan, and Latin America and are completing development of a new cannister system to drive growth in 2022.

Available for Acquisition #201407

Summary Financial Information

	2018	2019	2020	2021YTD (Oct. 1 st)	2021E	2022E
Sales	\$2.11M	\$1.87M	\$2.39M	\$3.62M	\$4.82M	\$8.60M
Gross Profit	\$1.35M	\$1.14M	\$1.58M	\$2.67M	\$3.24M	\$5.47M
EBITDA (adj.)	\$0.09M	\$0.16M	\$0.74M	\$1.70M	\$2.05M	\$3.11M

Contact Information

For more information, please contact:
ACT Capital Advisors, LLC
7525 SE 24th Street, Suite 630
Mercer Island, WA 98040

Interested parties should execute the attached Non-Disclosure Agreement (NDA) and return to ACT Capital Advisors with a written request to receive the Confidential Information Memorandum (CIM).

NDA's and CIM requests should be submitted to:



Jeff Zanardi
Managing Director
[jzanardi@actcapitaladvisors.com](mailto:τζanardi@actcapitaladvisors.com)
(408) 832-7241



Kevin Outcalt
Managing Director
koutcalt@actcapitaladvisors.com
(925) 785-9486